LUZHU BIOTECH-B (02480) announced its interim results, reporting a net loss of 61.62 million yuan, a decrease of 20.6% compared to the same period last year.

LUZHU BIOTECH-B (02480) announced its mid-term results for 2026, reporting other income of 6.762 million yuan, an increase of 39.4% year-on-year; research and development expenses of 30.331 million yuan, a decrease of 39.7% year-on-year; a net loss of 61.622 million yuan, a decrease of 20.6% year-on-year; and a loss per share of 0.31 yuan. The announcement stated that the growth in other income was primarily due to an increase in government subsidies and rental income, partially offset by a decrease in interest income and sales revenue from immunoassay test kits. The reduction in research and development expenses was mainly attributable to the relationship between R&D spending and the progress of the R&D pipeline, as most pipeline products are in the preclinical stage, leading to lower recorded R&D expenses.